Maryland Tech Council and BIOQuébec collaborate to promote life sciences

BIOQuébec and Maryland Tech Council Forge New Partnership to Advance Life Sciences

BIOQuébec and the Maryland Tech Council (MTC) are delighted to announce a new Memorandum of Understanding (MOU) that will enhance cooperation and collaboration between life sciences sectors in Québec and Maryland. This partnership aims to foster mutual benefits and strengthen biopharma and biotech industries in both regions through shared information and opportunities. The MOU establishes […]

Merck Signs MoU with KAIST to Further Scientific Partnership in South Korea


Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Technology (KAIST). The academia-industry cooperation aims to advance the research and development ecosystem in South Korea for industrial applications. “Our collaboration with KAIST is an important step towards accelerating the biotechnology ramp-up […]

Cognivia announces strategic EUR 15.5Mln funding

Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML Solutions

Cognivia, an innovative AI company dedicated to reshaping pharmaceutical and biotech clinical research through cutting edge AI-ML algorithms, announced a significant investment milestone. Vesalius Biocapital IV, SFPIM (Société Fédérale de Participations et d’Investissement) and WE (Wallonie Entreprendre) have committed strategic investments to drive Cognivia’s mission to “quantify the power of the mind” to optimize and […]

Kenai Therapeutics announces USD 82Mln series A financing

Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders, today announced an $82 million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures. […]

STEMCELL Technologies to acquire all assets of SQZ Biotechnologies Company

STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company

STEMCELL Technologies announced the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a Massachusetts-based biotech known for its game-changing method of introducing a variety of therapeutic cargo into cells by squeezing them (mechanoporation) rather than using electricity (electroporation). This transaction, which was approved by SQZ shareholders today, marks another significant milestone for STEMCELL, Canada’s […]

Prothena appoints Daniel G. Welch as Director and Chair Designate

Daniel G. Welch as Director and Chair Designate, Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced yesterday the appointment of Daniel G. Welch to its Board of Directors as an independent director and Chair Designate following a comprehensive search process in connection with the board’s regular succession planning. Upon election […]

Matica Bio designates Paul Kim as CEO

Paul Kim, Matica Bio's new CEO

Matica Biotechnology, Inc., a contract development and manufacturing organization (CDMO) of cell and gene therapies (CGTs), yesterday announced the appointment of Paul Kim as chief executive officer (CEO). As incoming CEO, Kim will manage daily operations and provide strategic direction to Matica Bio as it rapidly expands its capacity and capabilities in the U.S. and […]

Molecular Partners and Orano Med collaborate to develop novel Radio-DARPin therapeutics

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a pioneer in targeted alpha therapy, have announced a collaboration to develop novel Radio-DARPin therapeutics (RDTs) that use Orano Med’s 212Pb radioisotope as a payload to selectively kill cancer cells. Both companies will leverage their […]

Bristol Myers Squibb acquires Karuna Therapeutics

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

Bristol Myers Squibb and Karuna Therapeutics, Inc. recently announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved […]

Henry Schein onboards Carole T. Faig as new independent Director

Carole T. Faig, Independent Director, Henry Schein

Henry Schein, Inc., a provider of health care solutions to office-based dental and medical practitioners, announced yesterday that its Board of Directors has appointed Carole T. Faig as an independent director to serve until the 2024 Annual Meeting of Stockholders in May, when she is expected to stand for re-election to the Board by a […]